~~<i id='5ABDFE119D'><strike id='5ABDFE119D'><tt id='5ABDFE119D'><pre id='5ABDFE119D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：hotspot 2025-09-07 06:44:36 - browse：39

Elite athletes really are different from you and me. Or, at least their gut microbes are.

Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particular microbe compared to 10 non-athletes. Levels of the microbe in question, Veillonella, spiked after an intense workout and bloomed even more after the marathon.

That was a lightbulb moment for the scientists because the bacterium is known for breaking down and eating lactate, a metabolite even ordinary runners equate with fatigue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： 3 questions for the future of Biden's cancer moonshot

hotspot

leisure time

entertainment

explore

PATRICKT.FALLON/AFPviaGettyImagesAsthetemperaturescool,theseasonofcolds,flu,andnowCovid-19isheatingu

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

7 people shot in DC, police say

Grail is spending more than ever lobbying Congress

Community addresses injustice for Long Island mothers

Bill would stop addiction treatment from triggering child abuse inquiry

Was Amgen transparent enough on FDA's concern on cancer drug?

knowledge

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Sports medicine is finally prioritizing gender equality

When women are denied an abortion, their children fare worse than peers

Cancer drug shortages should be causing more outrage

Australia's humpback populations rebound raising hopes of marine scientists

Continuity nursing helped my family in our darkest PICU moments

Doctor appointment wait times are getting worse

Psychedelics group wrestles with new pharma identity

Liquid biopsy for lung cancer is launched by Delfi

hotspot

Meta looks to target Twitter with a rival app called Threads

Option Care buys Amedisys in $3.6 billion home care deal

Was Amgen transparent enough on FDA's concern on cancer drug?

Senate panel eyes new effort on drug shortages

Meta looks to target Twitter with a rival app called Threads

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

hotspot

leisure time

entertainment

explore